Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer

Version 1 : Received: 9 April 2021 / Approved: 12 April 2021 / Online: 12 April 2021 (12:28:10 CEST)

A peer-reviewed article of this Preprint also exists.

Gleicher, S.; Porter, B.A.; Nath, D.; Li, G.; Khanna, R.; Goldberg, H.; Kortylewski, M.; Bratslavsky, G.; Kotula, L. Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer. Cancers 2021, 13, 2426. Gleicher, S.; Porter, B.A.; Nath, D.; Li, G.; Khanna, R.; Goldberg, H.; Kortylewski, M.; Bratslavsky, G.; Kotula, L. Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer. Cancers 2021, 13, 2426.

Journal reference: Cancers 2021, 13, 2426
DOI: 10.3390/cancers13102426

Abstract

Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay, however almost all patients will eventually transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC generally develop symptomatic metastatic disease (mCRPC) and incur mortality several years later. Prior to metastatic disease, men acquire non-metastatic CRPC (nmCRPC) which lends the unique opportunity for intervention to delay disease progression and symptoms. This review addresses current therapies for nmCRPC, as well as novel therapeutics and pathway strategies targeting men with nmCRPC.

Subject Areas

prostate cancer; castrate resistance, non-metastatic CRPC, clinical trial, epithelial mesenchymal transition, STAT3

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.